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“replacement” in this context is rather a
semantic one. In our series of 4 patients,
with 3 having had a transannular patch at
tetralogy of Fallot repair and one having
had a commissurotomy at repair of val-
vular pulmonary stenosis, all patients
have had a native, although stenotic, pul-
monary valve. Therefore by implanting a
pulmonary valve prosthesis within the
native valve, this valve and its function
are being replaced. With regard to an
enlarged right ventricular outflow tract
(RVOT), we believe that reduction plasty
is necessary in patients with a diameter of
greater than 28 mm for 2 reasons. First,
the Shelhigh Injectable Valve is available
in a maximal size of 33 mm. Following
the recommendations of Schreiber with
oversizing of at least 2 mm would mean
that patients with an RVOT of greater
than 31 mm could not be treated with this
new technique. However, it is this subset
of patients with chronic pulmonary regurgi-
tation that present typically with enlarged
RVOT and profit the most from this
method. Second, it is well known from the
literature that an enlarged RVOT is delete-
rious for the function of the right ventricle1
and might be a source for ventricular ar-
rhythmias and consecutive sudden death.2,3
Surgical treatment should therefore not
only be focused on pulmonary valve re-
placement, but also additional problems
should be addressed concomitantly. Be-
cause reduction plasty can also be done
safely and easily off pump, does not lead to
stenosis, and reshapes a conical RVOT to a
more tubular form in which the inserted
valve prosthesis finds better seating, we
would still recommend it. We of course
also perform an in-depth analysis of right
ventricular function and the morphology of
the RVOT by means of transesophageal
and transthoracic echocardiography and
magnetic resonance imaging preopera-
tively to assess the feasibility of this pro-
cedure in an individual patient.
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Tracheal stents in patients with
malignancy
To the Editor:
We read with interest the article by Sihvo
and colleagues1 titled “Fatal Fistula Be-
tween the Trachea and the Brachiocephalic
Artery: Late Complication of a Second-
Generation, Self-Expanding Metallic Tra-
cheal Stent.”
In recent years, the use of this new type
of stent has become more frequent, with a
consequent improvement of quality of life
and survival in patients affected by inoper-
able malignant disease or benign disor-
ders. The use of these stents has been en-
couraged by their easy deployment, which
often can be performed through a fiberoptic
bronchoscope. However, they are expen-
sive, and sometimes their use can be ques-
tioned in patients with a relatively limited
life expectancy and tendency to neoplastic
tissue growth. The second-generation self-
expanding metallic stents reach the largest
diameter in 36 to 48 hours after deploy-
ment. Covered stents should be preferred,
especially in the case of malignancy, to
avoid tissue grow within the mesh of the
stent and formation of granulations.
Traditionally, we have preferred sili-
cone stents (Dumon stents; Novatech, La
Ciotat Cedex, France), having placed more
than 200 of them over a period of 13 years.
Erosion was never a complication. Minor
complications were secretion retention and
granulations on one edge of the stent (1%
in the neoplastic population); also, dis-
placement never happened in patients with
cancer. We also have a small experience
with self-expandable stents (12 patients
with 14 stents); however, they were used in
a very well selected group of patients with
difficult anatomic situations, and most of
them had a tortuous posttransplant bron-
chial stenosis with a malacic component.
In the text of the article it is not clear
whether the first two stents, and in partic-
ular the first one used in that patient, were
covered or not. Could the authors clarify
this?
Again, we encourage the use of silicone
stents in patients with malignant tumors;
they are less expensive, easy to place, and
can be removed or changed if required by
the clinical situation.
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Reply to the Editor:
We thank Drs Anile, Giacomo, and Venuta
for their valuable comments, encouraging
the use of silicone stents in patients with
malignant disease. They state that silicone
stents are less expensive, easy to place, and
can be removed or changed if required by
the clinical situation.
If possible, surgery is the preferred treat-
ment for benign and malignant tracheal
obstruction. However, many patients have
inoperable tumors and must undergo palli-
ation, for example, with stenting, either ex-
pandable metallic stents or silicone stents.
Lately, we have used second-generation me-
tallic stents placed with the aid of a flexible
endoscope because patients with silicone
stents seem to have severe secretion prob-
lems and migration. These complications
lead to stent obstruction necessitating rein-
terventions with a rigid bronchoscope, in-
creasing the total costs of the initially lower
cost treatment. We know the disadvantages
of second-generation self-expanding stents
(tumor ingrowth, especially in uncovered
stents, and difficult removal).1 However,
the quality of the short life after placement
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